Determining the optimal timing of adjuvant chemotherapy initiation after concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma

被引:0
|
作者
Cheng, H. [1 ,2 ]
Chen, J. [1 ,2 ]
Jia, G. [1 ,2 ]
Liang, Y. [1 ,2 ]
Li, Y. [1 ,2 ]
Chen, Y. [1 ,2 ]
Lin, J. [1 ,2 ]
Wang, P. [1 ,2 ]
Chen, Q. [1 ,2 ]
Tang, L. [1 ,2 ]
Mai, H. [1 ,2 ]
Liu, L. [1 ,2 ]
机构
[1] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Key Lab Nasopharyngeal Carcinoma Diag & Therapy, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Peoples R China
[2] Sun Yat Sen Univ, Canc Ctr, Dept Nasopharyngeal Carcinoma, 651 Dongfeng East Rd, Guangzhou 510060, Guangdong, Peoples R China
关键词
locoregionally advanced nasopharyngeal carcinoma; adjuvant chemotherapy initiation; optimal timing; progression-free survival; RANDOMIZED-TRIAL; STAGE-III; CANCER; SURVIVAL; RADIOTHERAPY; ASSOCIATION; MULTICENTER; TIME; DNA;
D O I
10.1016/j.esmoop.2024.103707
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Studies on several malignancies have suggested that the time to commencement of adjuvant chemotherapy (AC) is associated with survival outcomes. There have, however, been no relevant reports of nasopharyngeal carcinoma (NPC). Patients and methods: This clinical study examined newly diagnosed patients between April 2017 and December 2020. The primary endpoint was progression-free survival (PFS). Inverse probability of treatment weighting was used to control for confounding factors. Cox models with restricted cubic splines, Kaplan-Meier method and log-rank tests were used to evaluate the relationship between AC timing and survival. Results: A total of 551 patients were identified [median age, 45 years (interquartile range 36-52 years); 383 (69.5%) male]. Restricted cubic splines demonstrated that the timing of AC initiation had a U-shaped association with PFS. The risk of disease progression decreased within 37 days and subsequently increased. From 37 to 90 days, each additional 7-day delay conferred worse PFS of 1.32 months {hazard ratio (HR): 1.14 [95% confidence interval (CI) 1.01-1.28], P = 0.04}. The cut-off value of the receiver operating characteristic curve for initiation was 69.5 days. At a median follow-up of 48 months, the PFS was significantly better in patients initiated within 69.5 days [HR: 2.18 (95% CI 1.17-4.06), log-rank P = 0.009], with a higher 3-year rate [78.8% (95% CI 75.1% to 82.7%) versus 59.0% (95% CI 42.2% to 82.5%)] than beyond 69.5 days. Positive results were also observed in secondary endpoints. The initiation group was an independent prognostic factor [HR: 2.28 (95% CI 1.42-3.66), P < 0.001]. Conclusions: The optimal timing of AC initiation is similar to 37 days after concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. A delay beyond 69.5 days is associated with compromised survival. Efforts should be made to address the reasons for delays and ensure the timely initiation of AC.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial
    Sun, Ying
    Li, Wen-Fei
    Chen, Nian-Yong
    Zhang, Ning
    Hu, Guo-Qing
    Xie, Fang-Yun
    Sun, Yan
    Chen, Xiao-Zhong
    Li, Jin-Gao
    Zhu, Xiao-Dong
    Hu, Chao-Su
    Xu, Xiang-Ying
    Chen, Yuan-Yuan
    Hu, Wei-Han
    Guo, Ling
    Mo, Hao-Yuan
    Chen, Lei
    Mao, Yan-Ping
    Sun, Rui
    Ai, Ping
    Liang, Shao-Bo
    Long, Guo-Xian
    Zheng, Bao-Min
    Feng, Xing-Lai
    Gong, Xiao-Chang
    Li, Ling
    Shen, Chun-Ying
    Xu, Jian-Yu
    Guo, Ying
    Chen, Yu-Ming
    Zhang, Fan
    Lin, Li
    Tang, Ling-Long
    Liu, Meng-Zhong
    Ma, Jun
    LANCET ONCOLOGY, 2016, 17 (11): : 1509 - 1520
  • [42] Significant survival benefit of adjuvant chemotherapy after concurrent chemoradiotherapy in locally advanced high-risk nasopharyngeal carcinoma
    Zhong-Guo Liang
    Xiao-Qian Chen
    Guo-Xiang Lin
    Bin-Bin Yu
    Kai-Hua Chen
    Qiu-Lu Zhong
    Si-Kai Nong
    Ling Li
    Song Qu
    Fang Su
    Wei Zhao
    Ye Li
    Xiao-Dong Zhu
    Scientific Reports, 7
  • [43] FACTORS AFFECTING SIGNIFICANT WEIGHT LOSS AFTER CONCURRENT CHEMORADIOTHERAPY FOLLOWED BY ADJUVANT CHEMOTHERAPY FOR LOCALLY ADVANCED NASOPHARYNGEAL CARCINOMA
    Ngamphaiboon, N.
    Mahaprom, K.
    Jiarpinitnun, C.
    Sirachainan, E.
    Shanatavasinkul, P.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : E28 - E28
  • [44] Significant survival benefit of adjuvant chemotherapy after concurrent chemoradiotherapy in locally advanced high-risk nasopharyngeal carcinoma
    Liang, Zhong-Guo
    Chen, Xiao-Qian
    Lin, Guo-Xiang
    Yu, Bin-Bin
    Chen, Kai-Hua
    Zhong, Qiu-Lu
    Nong, Si-Kai
    Li, Ling
    Qu, Song
    Su, Fang
    Zhao, Wei
    Li, Ye
    Zhu, Xiao-Dong
    SCIENTIFIC REPORTS, 2017, 7
  • [45] Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial
    Cao, Su-Mei
    Yang, Qi
    Guo, Ling
    Mai, Hai-Qiang
    Mo, Hao-Yuan
    Cao, Ka-Jia
    Qian, Chao-Nan
    Zhao, Chong
    Xiang, Yan-Qun
    Zhang, Xiu-Ping
    Lin, Zhi-Xiong
    Li, Wei-Xiong
    Liu, Qing
    Qiu, Fang
    Sun, Rui
    Chen, Qiu-Yan
    Huang, Pei-Yu
    Luo, Dong-Hua
    Hua, Yi-Jun
    Wu, Yi-Shan
    Lv, Xing
    Wang, Lin
    Xia, Wei-Xiong
    Tang, Lin-Quan
    Ye, Yan-Fang
    Chen, Ming-Yuan
    Guo, Xiang
    Hong, Ming-Huang
    EUROPEAN JOURNAL OF CANCER, 2017, 75 : 14 - 23
  • [46] Adjuvant chemotherapy prior to postoperative concurrent chemoradiotherapy for locoregionally advanced head and neck cancer
    Choe, Kevin S.
    Salama, Joseph K.
    Stenson, Kerstin M.
    Blair, Elizabeth A.
    Witt, Mary Ellyn
    Cohen, Ezra E. W.
    Haraf, Daniel J.
    Vokes, Everett E.
    RADIOTHERAPY AND ONCOLOGY, 2010, 97 (02) : 318 - 321
  • [47] Comparison of Concurrent Chemoradiotherapy Followed by Adjuvant Chemotherapy Versus Concurrent Chemoradiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma: a Meta-analysis of 793 Patients from 5 Randomized Controlled Trials
    Liang, Zhong-Guo
    Zhu, Xiao-Dong
    Zhou, Zhi-Rui
    Qu, Song
    Du, You-Qin
    Jiang, Yan-Ming
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2012, 13 (11) : 5747 - 5752
  • [48] Concurrent chemoradiotherapy followed by adjuvant chemotherapy compared with concurrent chemoradiotherapy alone for the treatment of locally advanced nasopharyngeal carcinoma: a retrospective controlled study
    Liang, Z.
    Zhu, X.
    Li, L.
    Qu, S.
    Liang, X.
    Liang, Z.
    Su, F.
    Li, Y.
    Zhao, W.
    CURRENT ONCOLOGY, 2014, 21 (03) : E408 - E417
  • [49] Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study
    Qiu, Wen-Ze
    Huang, Pei-Yu
    Shi, Jun-Li
    Xia, Hai-Qun
    Zhao, Chong
    Cao, Ka-Jia
    CHINESE JOURNAL OF CANCER, 2016, 35
  • [50] Optimal sequencing of chemotherapy with chemoradiotherapy based on TNM stage classification and EBV DNA in locoregionally advanced nasopharyngeal carcinoma
    Liu, Li-Ting
    Chua, Melvin L. K.
    Tao, Yungan
    Tang, Lin-Quan
    Mai, Hai-Qiang
    CANCER COMMUNICATIONS, 2019, 39 (01):